Latest News

EpidStrategies’ epidemiologists have collaborated with other researchers on three publications that describe healthcare utilization in 80,000 infants covered by Medicaid, as well as RSV epidemiology and testing patterns among 1000–5000 infants tracked in real-time clinical and viral surveillance across four healthcare systems. https://academic.oup.com/ofid/article/11/4/ofae174/7633290 https://www.sciencedirect.com/science/article/pii/S1047279724000619 https://onlinelibrary.wiley.com/doi/10.1111/irv.13298 Please contact Mina Suh (msuh@epidstrategies.com) for information on our RSV research program.

ToxStrategies is pleased to announce that Dr. Nate Collins has joined our firm as a Senior Consultant. Dr. Collins has 25 years’ experience in the industry, working at four major pharmaceutical companies. He is a trained veterinary clinical pathologist and has held leadership roles in diverse areas, including pathology, immunotoxicology, investigative/mechanistic toxicology, and genetic toxicology. Most recently, Dr. Collins served as vice president for nonclinical safety, where he was responsible for the nonclinical strategy for read more…

ToxStrategies LLC, EpidStrategies, a Division of ToxStrategies LLC, and Modality Solutions are pleased to announce 2024 promotions for nearly three-dozen of our scientists, epidemiologists, statisticians, engineers, and project coordinators! We appreciate their dedication, hard work, leadership, and technical excellence, and we celebrate their well-deserved success! ToxStrategies LLC is proud to foster the professional development of our staff in the scientific consulting arena. Click below for profile links.

ToxStrategies is excited to be attending, exhibiting, and hosting a round table at the World Orphan Drug Congress (WODC), April 23–25, 2024. This year’s congress is at the Boston Convention and Exhibit Center. Come by and see us at Booth 537! Also, join us at Roundtable 06, on Wednesday, April 24, at 14:15, when our experts will discuss, “Meeting the Challenges of Fast-Track Approval for Orphan Drugs.” Senior Managing Scientist Amy Kimzey, PhD, DABT, will read more…

The Food and Drug Administration has released a Final Guidance for Industry to address some ongoing issues with procedures and timing for submitting New Dietary Ingredient Notifications (NDINs). Since 1994, a manufacturer wishing to market a New Dietary Ingredient has needed to file a dossier (Notification) to document the manufacturer’s reasonable expectation of the ingredient’s safety. In 2011, FDA issued a draft NDI guidance, which was met with resistance on a number of fronts; FDA read more…

ToxStrategies is excited to be attending, presenting, and exhibiting at the Society of Toxicology’s 63rd Annual Meeting and ToxExpo, March 9th 2024, to March 14, 2024. This year’s meeting is in Salt Lake City, Utah, at the Salt Palace Convention Center. Come by and see us at Booth #932!  

HEORStrategies’ Dr. Naomi Sacks is a co-author on a study of healthcare resource use and costs in cardiac arrhythmia patients with paroxysmal supraventricular tachycardia (PSVT) who undergo catheter ablation.  Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author of a study just published in the International Journal of Cardiology. The researchers were interested in the effects of catheter ablation, a surgical procedure considered curative, on healthcare resource utilization (HRU) and expenditures for patients newly diagnosed read more…

On January 8, 2024, EPA issued a new framework for identifying eye irritation or corrosion hazards for new chemicals reviewed under the Toxic Substances Control Act (TSCA). In their framework, EPA states that the New Chemicals Program “does not encourage the prospective use of the in vivo eye irritation test using live rabbits (e.g., the Draize test).” Thus, the framework supports EPA’s mandate under TSCA to promote the development and implementation of alternative test methods read more…